<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03166241</url>
  </required_header>
  <id_info>
    <org_study_id>ACDR</org_study_id>
    <nct_id>NCT03166241</nct_id>
  </id_info>
  <brief_title>Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction.</brief_title>
  <official_title>Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction and Correlation With Disease Severity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adverse cutaneous drug reactions are undesirable and typically unanticipated reactions&#xD;
      independent of the intended therapeutic purpose of a medication. It may be either immunologic&#xD;
      (eg, drug allergy) or non-immunologic. Adverse cutaneous drug reaction produce a wide range&#xD;
      of clinical manifestations such as pruritus, maculopapular eruptions, urticaria, angioedema,&#xD;
      phototoxic and photo allergic reactions, fixed drug reactions, erythema&#xD;
      multiforme,vesiculobullous reactions (eg, Stevens-Johnson syndrome and toxic epidermal&#xD;
      necrolysis) and serum sickness .They must be considered in the differential diagnosis of&#xD;
      sudden symmetric eruption&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Erythema multiforme is an acute immune mediated disorder It is a type IV hypersensitivity&#xD;
      reaction leading to dermal vasculitis. Erythema multiforme major usually as a result of&#xD;
      medications such as sulphonamides, non-steroidal anti-inflammatories and penicillin and there&#xD;
      is skin and mucosal involvement.&#xD;
&#xD;
      Steven-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are considered a spectrum&#xD;
      of acute life-threatening mucocutaneous reactions that differ only in severity. Both diseases&#xD;
      are characterized by mucous membrane and skin involvement, are often caused by medications&#xD;
      and are collectively known as epidermal necrolysis or scalded skin syndrome.Stevens-Johnson&#xD;
      syndrome (SJS) is classified as an epidermal loss &lt;10% of the body surface area.Toxic&#xD;
      Epidermal Necrolysis (TEN) is indicated by &gt;30% body surface area erosion. The range of&#xD;
      epidermal loss between 10% and 30% is called Stevens-Johnson syndrome-Toxic Epidermal&#xD;
      Necrolysis (SJS-TEN) overlap. Severity of illness score [Score of Toxic Epidermal&#xD;
      Necrolysis(TEN) ] has been devised to predict prognosis in patients with Epidermal&#xD;
      Necrolysis.This scoring system addresses 7 prognostic factors: age, malignancy, heart&#xD;
      rate,Body Surface Area involved, serum urea, serum glucose and serum bicarbonate levels.&#xD;
&#xD;
      Interleukin-21 regulates both innate and adaptive immune responses and it is not only has key&#xD;
      roles in antitumour and antiviral responses that promote the development of autoimmune&#xD;
      diseases and inflammatory disorders. It is recently discovered member of the type 1 cytokine&#xD;
      family which is produced by activated clusters of differentiation 4+ T cells ,Natural killer&#xD;
      cells and follicular helper T cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the patients with severe adverse cutaneous drug reaction who show change in serum interleukin 21 before and after therapy</measure>
    <time_frame>one month</time_frame>
    <description>blood sample will be taken from patients</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Adverse Cutaneous Reaction to Alternative Medical Therapy</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>measure serum interleukin 21 level in patients with severe adverse drug reaction who show change in serum interleukin 21 before and after therapy the following investigation will be done at the begning of the study to patients: Complete Blood Picture Erythrocyte Sedimentation Rate Random blood sugar Liver function tests Kidney function tests</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>compare serum interleukin 21 level in patients with severe adverse drug reaction and healthy control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum interleukin 21</intervention_name>
    <description>it is cytokine used as a marker to detect it's level in patients with adverse drug reactions</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Complete Blood Picture</intervention_name>
    <description>It is a blood sample will taken from patients to detect any abnormalities in blood component at the start of the study</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Liver function test</intervention_name>
    <description>It is a blood sample will taken from patients to detect any associated liver disease at the start of the study</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Random Blood Sugar</intervention_name>
    <description>measure blood sugar in patients included in the study at the start of the study</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Erythrocyte Sedimentation Rate</intervention_name>
    <description>blood sample will be taken from patients to detect any abnormalities in erythrocyte sedimentation rate at the start of the study</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Kidney function tests</intervention_name>
    <description>blood sample will be taken from patients to detect any kidney disease before the start of the study</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20 patients presenting with adverse cutaneous drug reaction (Erythema multiforme, SJS&#xD;
             and TEN )&#xD;
&#xD;
          -  Patients with definite drug history.&#xD;
&#xD;
          -  Both sex will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of topical or systemic treatment (corticosteroids,&#xD;
             intralesional steroid injection, immunosuppressive therapy).&#xD;
&#xD;
          -  Patients within 4 weeks of the study.&#xD;
&#xD;
          -  Patients receiving phototherapy within 6 months of the study.&#xD;
&#xD;
          -  Diabetic patients&#xD;
&#xD;
          -  Anaemic patients&#xD;
&#xD;
          -  Thyroid disorders,&#xD;
&#xD;
          -  Chronic liver or Renal diseases&#xD;
&#xD;
          -  Atopy and Parathyroid disorders.&#xD;
&#xD;
          -  Patients with known autoimmune diseases or cancer.&#xD;
&#xD;
          -  Pregnant or lactating womens.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fathya Ali, MD</last_name>
    <phone>01000197217</phone>
    <email>Askar21@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanan Ahmed, MD</last_name>
    <phone>01064447881</phone>
    <email>hanan-morsy2003@yahoo.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Farshchian M, Ansar A, Zamanian A, Rahmatpour-Rokni G, Kimyai-Asadi A, Farshchian M. Drug-induced skin reactions: a 2-year study. Clin Cosmet Investig Dermatol. 2015 Feb 9;8:53-6. doi: 10.2147/CCID.S75849. eCollection 2015.</citation>
    <PMID>25709487</PMID>
  </results_reference>
  <results_reference>
    <citation>Hidajat C, Loi D. Drug-mediated rash: erythema multiforme versus Stevens-Johnson syndrome. BMJ Case Rep. 2014 Sep 22;2014. pii: bcr2014205543. doi: 10.1136/bcr-2014-205543.</citation>
    <PMID>25246464</PMID>
  </results_reference>
  <results_reference>
    <citation>Ellender RP, Peters CW, Albritton HL, Garcia AJ, Kaye AD. Clinical considerations for epidermal necrolysis. Ochsner J. 2014 Fall;14(3):413-7. Review.</citation>
    <PMID>25249808</PMID>
  </results_reference>
  <results_reference>
    <citation>Gong F, Su Q, Pan YH, Huang X, Shen WH. The emerging role of interleukin-21 in allergic diseases (Review). Biomed Rep. 2013 Nov;1(6):837-839. Epub 2013 Sep 12.</citation>
    <PMID>24649038</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2017</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>MAHanna</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

